ICER Suggests Big Price Cut For Novartis’s New PNH Drug

Feb 01 2024

• By Alaric DeArment

Listen to this article

The pricing watchdog said 94% of Fabhalta’s price comes from offsetting the cost of AstraZeneca’s Ultomiris, while Novartis said ICER’s analysis has “substantial challenges.”

• Source: Shutterstock

Novartis AG would have to drop the list price of Fabhalta (iptacopan) for paroxysmal nocturnal hemoglobinuria (PNH) by nearly three quarters to make it more cost-effective, as much of its price is driven by the high prices of the anti-C5 inhibitors used for PNH, according to a new report by the Institute for Clinical and Economic Review (ICER), which also recommended a lower list price for AstraZeneca PLC’s danicopan.

The drug-pricing watchdog posted a revised evidence report assessing the clinical effectiveness and value of Fabhalta and danicopan and plans...

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico
Nov 06 2025
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Sponsored By
Nancy Tests SPARC-931 Part 8
This is a short description. This is a short description.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.